TRINETRA › Sectors › Healthcare
GlaxoSmithKline Pharmaceuticals Limited (GLAXO) — share price, P/E and fundamentals
GlaxoSmithKline Pharmaceuticals Limited (NSE: GLAXO) closed at ₹2,508.70 on 30 Oct 2026, -8.5% over one year, against a 52-week range of ₹2,088.10 – ₹3,120.70.
In the quarter ended 30 Jun 2026 (consolidated, filed 3 Aug 2026) it reported revenue of ₹938 cr and net profit of ₹237 cr, a 25.3% net margin; revenue grew 16.6% and profit grew 15.6% year on year.
On four consecutive filed quarters its trailing P/E is 39.8; since 13 May 2025 its own P/E has ranged from 35.0 to 63.6 (median 45.6), and today's reading is higher than 17% of those 363 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 41.8%, ROCE 50.8%, debt-to-equity 0.00, Piotroski F-score 7 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 87% of 63 sector peers; PBT margin higher than 89% of 63 sector peers; ROE higher than 98% of 63 sector peers.
Key figures
| Last close | ₹2,508.70 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -11.3% / +1.5% / -8.5% |
| 52-week low – high | ₹2,088.10 – ₹3,120.70 |
| Market capitalisation | ₹42,500 cr |
| Trailing P/E | 39.8 |
| Price / book | 18.74 |
| EV / EBITDA | 27.2 |
| Earnings yield | 2.5% |
| TTM EPS | ₹63.05 |
| TTM net profit | ₹1,068 cr |
| Quarter revenue | ₹938 cr |
| Quarter net profit | ₹237 cr |
| Net margin | 25.3% |
| Revenue growth (YoY) | +16.6% |
| Profit growth (YoY) | +15.6% |
| Return on equity | 41.8% |
| ROCE | 50.8% |
| Debt / equity | 0.00 |
| Current ratio | 2.13 |
| Free cash flow | ₹848 cr |
| Piotroski F-score | 7 / 9 |
| Average daily turnover (50 days) | ₹14.5 cr |
Against Healthcare peers
| Metric | GLAXO | Peer median | Percentile |
|---|---|---|---|
| Net margin | 25.27 | 12.67 | 87 |
| PBT margin | 34.36 | 17.57 | 89 |
| ROE | 41.84 | 13.86 | 98 |
| ROCE | 50.84 | 16.59 | 98 |
| Debt / equity | 0.00 | 0.11 | 12 |
| Cash conversion | 0.87 | 1.25 | 23 |
| Trailing P/E | 39.79 | 43.26 | 42 |
| P/B | 18.74 | 5.88 | 97 |
Questions
What is the P/E ratio of GlaxoSmithKline Pharmaceuticals Limited?
GlaxoSmithKline Pharmaceuticals Limited's trailing P/E is 39.8, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 13 May 2025 its P/E has ranged 35.0–63.6.
What were GlaxoSmithKline Pharmaceuticals Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, GlaxoSmithKline Pharmaceuticals Limited reported revenue of ₹938 cr and net profit of ₹237 cr (consolidated), filed with the exchange on 3 Aug 2026.
What is GlaxoSmithKline Pharmaceuticals Limited's ROE?
Return on equity is 41.8% based on the balance sheet dated 31 Mar 2026.
Does GlaxoSmithKline Pharmaceuticals Limited have debt?
Debt-to-equity is 0.00 on the balance sheet dated 31 Mar 2026.
What is GLAXO's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, GLAXO traded between ₹2,088.10 and ₹3,120.70.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.